Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate
gene expression and are involved in cancer pathogenesis. Over the last years, several BET …

Pancreatic cancer is a highly lethal form of digestive malignancy that poses significant
health risks to individuals worldwide. Chemotherapy‐based comprehensive treatment is the …

Tissue damage increases the risk of cancer through poorly understood mechanisms. In
mouse models of pancreatic cancer, pancreatitis associated with tissue injury collaborates …

The signature features of pancreatic ductal adenocarcinoma (PDAC) are its
fibroinflammatory stroma, poor immune activity, and dismal prognosis. We show that acute …

Aim: To explore the anticancer activity of a novel BRD4 protein degrader ARV-825 (ARV)
and its nanoformulation development (ARV-NP) for treatment of pancreatic cancer. Materials …

Objective Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an
overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear …

Surgical resection, when combined with chemotherapy, has been shown to significantly
improve the survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) …

Genetic studies have advanced our understanding of pancreatic cancer at a mechanistic
and translational level. Genetic concepts and tools are increasingly starting to be applied to …

Pancreatic ductal adenocarcinoma (PDAC) remains a major health problem because it
induces almost systematic mortality. Carcinogenesis begins with genetic aberrations which …

CTLA-4 is an immune checkpoint expressed on active anticancer T cells. When it combines
with its ligand B7 on dendritic cells, it inhibits the activity of the T cells. The Bromo-and Extra …